Aequus Pharmaceuticals Inc - Asset Resilience Ratio
Aequus Pharmaceuticals Inc (AQS) has an Asset Resilience Ratio of 4.11% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Aequus Pharmaceuticals Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Aequus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Aequus Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aequus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AQS market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$44.85K | 4.11% |
| Total Liquid Assets | CA$44.85K | 4.11% |
Asset Resilience Insights
- Limited Liquidity: Aequus Pharmaceuticals Inc maintains only 4.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aequus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aequus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Aequus Pharmaceuticals Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Aequus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 4.13% | CA$44.85K ≈ $32.44K |
CA$1.09 Million ≈ $785.76K |
+1.48pp |
| 2022-12-31 | 2.65% | CA$44.85K ≈ $32.44K |
CA$1.69 Million ≈ $1.22 Million |
+1.62pp |
| 2021-12-31 | 1.03% | CA$44.89K ≈ $32.47K |
CA$4.35 Million ≈ $3.15 Million |
+1.03pp |
| 2020-12-31 | 0.00% | CA$123.00 ≈ $88.98 |
CA$3.13 Million ≈ $2.27 Million |
-31.81pp |
| 2017-12-31 | 31.81% | CA$850.00K ≈ $614.88K |
CA$2.67 Million ≈ $1.93 Million |
-- |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more